Publications > Journals > Journal of Clinical and Translational Hepatology > Special Feature

Time: May 24, 2022

Journal: Journal of Clinical and Translational Hepatology

Special Issue: Integrative Omics Study for Clinical Liver Disease

Guest Editor-in-Chief: Prof. Shu-Sen Zheng

Guest Editors: Zheng-Tao Liu, Beng Yang, Ya-Feng Zhu, Sunjae Lee, Muhammad Arif

Status: Open

Submission deadline: October 31, 2022

Publication date: An article will be published online as soon as it is accepted.

Guest Editor-in-Chief Profiles:


Shu-Sen Zheng

Academician of the Chinese Academy of Engineering, Professor of Surgery, renowned surgical specialist in the fields of organ transplantaiton and hepato-pancreato-biliary surgery. To date, he has completed 3400 liver transplantation surgeries. He established the Hangzhou Criteria for HCC recipient selection for liver transplantation and the strategy for the prevention and management of HBV recurrence after liver transplantation. He has published more than 400 articles in international journals. Prof. Zheng is the Editor-in-Chief of several monographs such as Liver Transplantation, Pancreas TransplantationManagement in Peri-operative Period of Liver Transplantation, etc. Prof. Zheng established the Chinese College of Transplantation Doctors and promoted several national projects for organ donation and allocation in China. Prof. Zheng also established a series of international collaborations (with Cleveland Clinic, UCLA, Stanford University, etc.), which achieved international approval for liver transplantation in China and accelerated the fusion of Chinese organ transplantation with the international organization. Prof. Zheng was awarded the honorary Academician of Surgery of Hong Kong award in 2012, and he is the first Chinese honorary professor at UCLA in the field of medicine.  

Guest Editors:


Zheng-Tao Liu

Associate Professor, Shulan International Medical College, Zhejiang Shuren University. Study interests: omics studies of clinical liver disease, molecular mechanisms for the effects of marginal grafts on the prognosis of recipients after liver transplantation.  


Beng Yang

First Affiliated Hospital, School of Medicine, Zhejiang University, specializes in the biology and oncology of liver cancer and biliary tract cancer as well as in liver injury mechanisms in liver transplantation and liver ischemia/reperfusion.  


Ya-Feng Zhu

Associate Professor, Sun Yat-sen Memorial hospital, Sun Yat-sen University. Study interests: clinical proteomics, biomarker discovery, and single-cell proteomics.  


Sunjae Lee

Assistant professor, School of Life Sciences, Gwangju Institute of Science and Technology (GIST), Study interests: Microbiome, Metabolism, Systems Biology, and Bioinformatics.  


Muhammad Arif

National Institute of Alcohol Abuse and Alcoholism, National Institutes of Health. Study Interests: multi-omics data analysis, biological networks, and machine learning applications in metabolic diseases.  

As a major cause of morbidity and mortality, clinical liver disease (CLD) has become a severely increasing global burden due to its occupancy of health resources for patient treatment. Many pharmacological approaches (such as targeted therapy) or surgical techniques (such as live transplantation and associating liver partition and portal vein ligation for staged hepatectomy [ALPPS]) may help to improve the prognosis of patients with CLD. However, the underlying pathological mechanism of disease and the rationality of these therapies have yet to be revealed. A comprehensive understanding of the mechanisms of the occurrence and development of CLD and the relevant therapeutic approaches will support efforts for better prevention and therapy from the perspective of precision medicine.

Omics technologies provide valid approaches to reveal the potential mechanism of CLD through studies of whole genome, transcriptome, proteome, metabolome and microbiome profiles. As these technologies have advanced, omics testing is now widely affordable and has therefore become a preferred option for the investigation of potential targets and pathways involved in the pathogenesis of diseases. Improved algorithms guarantee data integration of multi omics data, and such integrated omics analyses provide more reliable data to guide further validation studies in vitro and in vivo. Multi-omics data also facilitate better prediction of the therapeutic effects of drugs and other interventions in CLD.

Therefore, we invite Original Articles, Reviews and Mini Reviews focusing on novel or the most-updated information on CLDs and relevant therapies based on via multi-omics approaches. The studies can be performed in human patients, in animal models, or in cell lines with the goal of characterizing the specific mechanisms underlying the pathogenesis, diagnosis, or treatment responses of CLDs, including chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma (HCC) via combinative approaches involving transcriptomics, proteomics, metabolomics, radiomics, etc. Multi-omics studies on key issues in liver transplantation (e.g., marginal grafts, ABO-mismatch, early allograft dysfunction and recurrence of primary liver disease) or other surgical techniques are especially welcome.

Research Topics
A. Multi-omics integrative analysis of issues related to the clinical application of marginal (macro-steatosis, aging, ABO-mismatched) grafts used for liver transplantation;
B. Genetics of non-alcoholic fatty liver disease and investigation of potential therapeutic intervention targets;
C. Potential mechanistic study on chronic liver diseases (e.g., CHC, CHB) based on integrative multi-omics research;
D. Application of omics data in selection of recipients for liver transplantation (comparison of Hangzhou/Milan/UCSF criteria for recipient selection for liver transplantation);
E. Mechanistic studies on innate and adaptive immunity in sterile inflammation during liver injury (e.g., liver transplantation and hepatic ischemia-reperfusion injury);
F. Cellular communication mechanisms (e.g., exosomes and metabolites) between nonparenchymal cells and parenchymal cells during tumorigenesis and development in liver cancers;
G. Metabolic reprogramming of tumor cells (such as amino acids and fatty acids) and induction of liver disease progression (including MAFLD, cirrhosis, and liver cancer); and
H. Interactive regulation of multiple tumor metabolism and signal transduction pathways in liver cancers.

The authors should refer to the Instructions for Authors in preparing the manuscript and kindly submit it through the Online Submission System directly.

Priority will be given with the same high standards of peer review and publication process for these articles. All publications will open free access to all readers. We guarantee that all accepted papers related to AI in Liver Disease will be highlighted in a special section on our website.

Online submission system:

Instructions for authors: Please state in a cover letter that the manuscript is being submitted for inclusion in the special issue ‘Integrative Omics Study for Clinical Liver Disease’ and follow the usual JCTH instructions. Please refer to:

For any inquiries, please contact the journal by e-mail: [email protected]